COVID-19 Top News – March 21, 2020

March 21, 2020

China starts clinical trials of Covid-19 vaccine (UrduPoint) – Mar 21, 2020 – “108 volunteers were divided into three groups of 36 persons each. The first group will receive a low dose of the developed vaccine, the second group will get a medium dose and the last group a high dose. The trials…will continue until the end of December….After getting the vaccine, the participants will be quarantined for 14 days and placed under constant medical supervision….Upon lifting the quarantine, they will be regularly examined for six months.”

 

Cepheid receives Emergency Use Authorization from FDA for rapid SARS-CoV-2 test (PRNewswire) – Mar 21, 2020 – “Cepheid…announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2…The test has been designed to operate on any of Cepheid’s more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.”

 

Avigan (favipiravir) / Fujifilm Holdings
Study shows an anti-viral flu drug to be effective in treating Covid-19 (Gilmore Health – The Brux10 Health Trust) – Mar 21, 2020 – “Favipiravir…has been found to be effective in treating COVID-19….They had found promising results from the use of Favipiravir or Avigan in 340 coronavirus patients. Zhang said the antiviral drugs proved to be effective and highly safe in the clinical trial conducted in Wuhan and Shenzhen….Additionally, the clinical trial in Wuhan reported a shorter febrile period from 4.2 days to 2.5 days.”

No Comments

Post a Comment

Comment
Name
Email
Website